ReShape Lifesciences is hosting its first Lap-Band Surgeon Summit from August 1st to 3rd, 2025, in Nashville, Tennessee. The summit, directed by Dr. Christine Ren-Fielding, a leading bariatric surgeon, will gather over 20 top Lap-Band surgeons to discuss the latest advancements in the Lap-Band procedure and its role in comprehensive weight management. The summit will focus on the benefits of the original Lap-Band and the newer Lap-Band 2.0 FLEX, the use of GLP-1 medications in patient care, and strategies for patient education and engagement.
This summit is important because it signifies ReShape Lifesciences’ commitment to revitalizing and expanding the Lap-Band franchise. It demonstrates a strategic focus on surgeon training and education, crucial for driving adoption of the next-generation Lap-Band 2.0 FLEX. The event also highlights the company’s recognition of the evolving weight management landscape, incorporating the latest medical therapies like GLP-1s into the Lap-Band ecosystem. This approach positions the Lap-Band as a relevant and modern weight-loss solution within a more holistic treatment paradigm.
The summit will feature presentations on the Lap-Band 2.0 FLEX, which has received positive initial feedback. This device represents a significant technological advancement with its self-adjusting technology, addressing previous limitations and integrating seamlessly with medical therapies like GLP-1s. The inclusion of GLP-1s in the discussion emphasizes a comprehensive approach to weight management, combining surgical and pharmaceutical interventions. This strategy reflects the current trend towards personalized weight loss solutions.
The Lap-Band Surgeon Summit represents a strategic investment in the future of the Lap-Band. By engaging leading surgeons and highlighting the latest technology, ReShape Lifesciences aims to re-establish the Lap-Band as a prominent tool in the fight against obesity. This proactive approach, combining technological advancement with a focus on surgeon education and patient engagement, may lead to renewed growth and market share for the Lap-Band franchise. The summit’s outcomes and subsequent surgeon adoption of the Lap-Band 2.0 FLEX will be key indicators of ReShape Lifesciences’ success in this endeavor.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
